Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
JSPR Analyst Ratings
Moderate Buy
5 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
JSPR Stock 12 Month Forecast
Average Price Target
$12.60
▲(433.90% Upside)
| Highest Price Target$25.00 | Average Price Target$12.60 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citizens JMP
$12→$6
Buy
154.24%
Upside
Reiterated
09/22/25
BTIG
$20→$7
Buy
196.61%
Upside
Reiterated
09/19/25
H.C. Wainwright
$20
Buy
747.46%
Upside
Reiterated
09/17/25
UBS
$29→$25
Buy
959.32%
Upside
Reiterated
08/15/25
William Blair
―
Hold
―
Reiterated
08/14/25
TD Cowen
―
Buy
―
Reiterated
08/13/25
TD Cowen Remains a Buy on Jasper Therapeutics (JSPR)We remain Buy. 3-6 Mos Delay To Ph2b Start From Potential Mfng Issue Is Surmountable – Briquilimab continues to show robust efficacy with clean safety across CSU/CIndU, and we remain constructive on the outlook despite the recent delay from potential manufacturing issues. Mgmt continues to look into whether there was a faulty product batch used in the 240mg Q8W and 240mg + 180mg Q8W cohorts of BEACON, and results from this investigation along with data from these cohorts (which will include 10-12 new patients as well as old patients switched over to a new batch) later this year will be key to defining the path ahead for briquilimab.
RBC Capital
$5
Hold
111.86%
Upside
Reiterated
08/13/25
Evercore ISI
$50→$20
Buy
747.46%
Upside
Reiterated
07/08/25
Cantor Fitzgerald
―
Hold
―
Downgraded
07/07/25
Oppenheimer
$65
Buy
2654.24%
Upside
Reiterated
06/16/25
Wells Fargo
$80
Buy
3289.83%
Upside
Reiterated
03/02/25
Barclays
$63
Buy
2569.49%
Upside
Initiated
02/27/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citizens JMP
$12→$6
Buy
154.24%
Upside
Reiterated
09/22/25
BTIG
$20→$7
Buy
196.61%
Upside
Reiterated
09/19/25
H.C. Wainwright
$20
Buy
747.46%
Upside
Reiterated
09/17/25
UBS
$29→$25
Buy
959.32%
Upside
Reiterated
08/15/25
William Blair
―
Hold
―
Reiterated
08/14/25
TD Cowen
―
Buy
―
Reiterated
08/13/25
TD Cowen Remains a Buy on Jasper Therapeutics (JSPR)We remain Buy. 3-6 Mos Delay To Ph2b Start From Potential Mfng Issue Is Surmountable – Briquilimab continues to show robust efficacy with clean safety across CSU/CIndU, and we remain constructive on the outlook despite the recent delay from potential manufacturing issues. Mgmt continues to look into whether there was a faulty product batch used in the 240mg Q8W and 240mg + 180mg Q8W cohorts of BEACON, and results from this investigation along with data from these cohorts (which will include 10-12 new patients as well as old patients switched over to a new batch) later this year will be key to defining the path ahead for briquilimab.
RBC Capital
$5
Hold
111.86%
Upside
Reiterated
08/13/25
Evercore ISI
$50→$20
Buy
747.46%
Upside
Reiterated
07/08/25
Cantor Fitzgerald
―
Hold
―
Downgraded
07/07/25
Oppenheimer
$65
Buy
2654.24%
Upside
Reiterated
06/16/25
Wells Fargo
$80
Buy
3289.83%
Upside
Reiterated
03/02/25
Barclays
$63
Buy
2569.49%
Upside
Initiated
02/27/25
Best Analysts Covering Jasper Therapeutics
1 Month
xxx
Success Rate
6/10 ratings generated profit
Average Return
+6.30%
assigned a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +6.30% per trade.
3 Months
xxx
Success Rate
6/15 ratings generated profit
Average Return
+2.83%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +2.83% per trade.
1 Year
2 Years
xxx
Success Rate
1/12 ratings generated profit
Average Return
-56.58%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 8.33% of your transactions generating a profit, with an average return of -56.58% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
JSPR Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
9
9
15
14
13
Buy
5
3
4
3
2
Hold
0
0
4
6
7
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
15
13
23
23
22
Each month's total comprises the sum of three months' worth of ratings.
JSPR Financial Forecast
JSPR Stock Forecast FAQ
What is JSPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Jasper Therapeutics’s 12-month average price target is 12.60.
What is JSPR’s upside potential, based on the analysts’ average price target?
Jasper Therapeutics has 433.90% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is JSPR a Buy, Sell or Hold?
Jasper Therapeutics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.
What is Jasper Therapeutics’s price target?
The average price target for Jasper Therapeutics is 12.60. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $5.00. The average price target represents 433.90% Increase from the current price of $2.36.
The highest analyst price target is $25.00 ,the lowest forecast is $5.00. The average price target represents 433.90% Increase from the current price of $2.36.
What do analysts say about Jasper Therapeutics?
Jasper Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of JSPR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.